BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business

BioMarin Pharma (BMRN) Tops Q4 EPS

February 27, 2023 4:05 PM EST

BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.00, which may not compare to the analyst estimate of ($0.06). Revenue for the quarter came in at $537.5 million versus the consensus estimate of $537.62 million.

GUIDANCE:

BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus... More